Sarosdy M F, Hutzler D H, Yee D, von Hoff D D
Division of Urology and Oncology, University of Texas Health Science Center, San Antonio 78284-7845.
J Urol. 1993 Dec;150(6):1950-5. doi: 10.1016/s0022-5347(17)35944-x.
TP-40 is a hybrid fusion protein produced by recombinant technology and consists of a molecule of transforming growth factor-alpha (TGF-alpha) fused to the Pseudomonas exotoxin PE-40. A panel of human and murine bladder cancer cell lines was found to be universally sensitive in vitro to TP-40 in a clonogenic assay. All lines expressed receptor for epidermal growth factor (EGF), though none demonstrated gene amplification for the EGF receptor. The sensitivity to TP-40 may be blocked by preexposure to EGF. Six human bladder tumors taken directly from patients were all sensitive in vitro to TP-40; these included well-differentiated tumors. TP-40 may prove to be effective as an intravesical agent in bladder cancer via selective targeting to cells that express EGF receptors, as do the majority of human bladder cancers.
TP - 40是一种通过重组技术产生的杂合融合蛋白，由与铜绿假单胞菌外毒素PE - 40融合的转化生长因子α（TGF - α）分子组成。在克隆形成试验中，一组人源和鼠源膀胱癌细胞系在体外对TP - 40普遍敏感。所有细胞系均表达表皮生长因子（EGF）受体，尽管没有一个显示出EGF受体的基因扩增。预先暴露于EGF可阻断对TP - 40的敏感性。直接取自患者的6例人膀胱肿瘤在体外对TP - 40均敏感；其中包括高分化肿瘤。TP - 40可能被证明作为一种膀胱内用药对膀胱癌有效，因为它能像大多数人类膀胱癌那样选择性地靶向表达EGF受体的细胞。
